Cargando…

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity

Molnupiravir is a β-d-N4-hydroxycytidine-5′-isopropyl ester (NHC) compound that exerts antiviral activity against various RNA viruses such as influenza, SARS, and Ebola viruses. Thus, the repurposing of Molnupiravir has gained significant attention for combatting infection with SARS-CoV-2, the etiol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yip, Ashley Jia Wen, Low, Zheng Yao, Chow, Vincent T. K., Lal, Sunil K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228778/ https://www.ncbi.nlm.nih.gov/pubmed/35746815 http://dx.doi.org/10.3390/v14061345

Ejemplares similares

Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication
por: Low, Zheng Yao, et al.
Publicado: (2022)

Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
por: Bai, Yuan, et al.
Publicado: (2022)

Molnupiravir and Its Antiviral Activity Against COVID-19
por: Tian, Lili, et al.
Publicado: (2022)

Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences
por: Singla, Shivali, et al.
Publicado: (2022)

SARS-CoV-2 Non-Structural Proteins and Their Roles in Host Immune Evasion
por: Low, Zheng Yao, et al.
Publicado: (2022)

Molnupiravir for COVID-19
Publicado: (2022)

On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia
por: Boretti, Alberto
Publicado: (2023)

Identification of antiviral antihistamines for COVID-19 repurposing
por: Reznikov, Leah R., et al.
Publicado: (2021)

SARS coronavirus outbreaks past and present—a comparative analysis of SARS-CoV-2 and its predecessors
por: Low, Zheng Yao, et al.
Publicado: (2021)

Engineered Ribosyl-1-Kinase Enables Concise Synthesis of Molnupiravir, an Antiviral for COVID-19
por: McIntosh, John A., et al.
Publicado: (2021)

Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic
por: Khiali, Sajad, et al.
Publicado: (2022)

An Engineered Cytidine Deaminase for Biocatalytic Production of a Key Intermediate of the Covid-19 Antiviral Molnupiravir
por: Burke, Ashleigh J., et al.
Publicado: (2022)

Potential for the Repurposing of Adamantane Antivirals for COVID-19
por: Butterworth, Roger F.
Publicado: (2021)

Efficacy and Safety of Molnupiravir in Mild COVID-19 Patients in India
por: Sinha, Shubhadeep, et al.
Publicado: (2022)

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis
por: Wen, Wen, et al.
Publicado: (2022)

Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir
por: Parums, Dinah V.
Publicado: (2022)

Vascularite rétinienne post-Covid-19 et Molnupiravir
por: Lassouli, I., et al.
Publicado: (2022)

Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system
por: Punekar, Madhura, et al.
Publicado: (2022)

Toward a Practical, Nonenzymatic Process for Investigational COVID-19 Antiviral Molnupiravir from Cytidine: Supply-Centered Synthesis
por: Gopalsamuthiram, Vijayagopal, et al.
Publicado: (2021)

Efficacy and safety of molnupiravir for COVID-19 patients
por: Fatima, Maurish, et al.
Publicado: (2022)

The effect of molnupiravir on post-acute outcome of COVID-19 survivors
por: Hsu, Wan-Hsuan, et al.
Publicado: (2023)

Clinical effectiveness of molnupiravir in patients with COVID-19 undergoing haemodialysis
por: Chang, Yi-Chin, et al.
Publicado: (2023)

Molnupiravir in COVID-19: A systematic review of literature
por: Singh, Awadhesh Kumar, et al.
Publicado: (2021)

What will be the role of molnupiravir in the treatment of COVID-19 infection?
por: Vitiello, Antonio, et al.
Publicado: (2021)

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
por: Jayk Bernal, Angélica, et al.
Publicado: (2021)

Molnupiravir: A new candidate for COVID‐19 treatment
por: Pourkarim, Fariba, et al.
Publicado: (2021)

PANORAMIC: important insights into molnupiravir use in COVID-19
por: Kidd, Michael R, et al.
Publicado: (2023)

Efficacy of repurposed antiviral drugs: Lessons from COVID-19
por: Martinez, Miguel Angel
Publicado: (2022)

Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses
por: Wang, Yining, et al.
Publicado: (2021)

Nudix hydrolase 18 catalyzes the hydrolysis of active triphosphate metabolites of the antivirals remdesivir, ribavirin, and molnupiravir
por: Jemth, Ann-Sofie, et al.
Publicado: (2022)

Three COVID-19 medications-remdesivir, molnupiravir and ritonavir-boosted nirmatrelvir-and serial liver biochemistries in 22, 456 subjects
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies
por: Zabidi, Nur Zawanah, et al.
Publicado: (2023)

Why Molnupiravir Fails in Hospitalized Patients
por: Brown, Ashley N., et al.
Publicado: (2022)

NZ's Pharmac negotiates deal for molnupiravir to treat COVID-19
Publicado: (2021)

Nirmatrelvir and Molnupiravir and Post–COVID-19 Condition in Older Patients
por: Fung, Kin Wah, et al.
Publicado: (2023)

The Benefits of Molnupiravir Treatment in Healthcare Facilities Patients with COVID-19
por: Cheng, Shih-Lung, et al.
Publicado: (2023)

Preferability of Molnupiravir, an Anti-COVID-19 Drug, toward Purine Nucleosides: A Quantum Mechanical Study
por: Ibrahim, Mahmoud A. A., et al.
Publicado: (2023)

Repurposing old drugs as antiviral agents for coronaviruses
por: Yang, Cheng-Wei, et al.
Publicado: (2020)

Molnupiravir: First Approval
por: Syed, Yahiya Y.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_me9p0hqvos0s0ipq1au2mfbn2m